Accueil Ernstrade Bourse Actualite Stock



Biofrontera AG is a Germany-based biopharmaceutical company that develops cosmetics and drugs for the care and treatment of dermatological and inflammatory diseases. The Company's product portfolio includes Belixos, used for the basic care in localized itching, atopic dermatitis or psoriasis; BF-RhodoLED, a lamp used after photodynamic therapy (PDT) treatment, and Ameluz, a medicament used in PDT of actinic keratoses. The Company has also three product candidates in clinical development, including BF-200 ALA (Phase II) for condyloma; BF-derm 1 (Phase II) for chronic, antihistamine-refractory urticaria; and BF-1 (Phase I) for migraine prophylaxis. Biofrontera AG has two wholly owned subsidiaries, Biofrontera Bioscience GmbH, involved in research, preclinical and clinical development, and Biofrontera Pharma GmbH, responsible for marketing and sales.


Hemmelrather Weg 201
+49214876320 (Phone)
+492148763290 (Fax)

Copyright  2013